Results 61 to 70 of about 6,539 (194)
We observed a novel therapeutic response with cabergoline in a male patient with a dopamine-secreting head and neck paraganglioma (HNPGL), macroprolactinoma and germline succinate dehydrogenase C mutation (SDHC).
Ziad Hussein +3 more
doaj +1 more source
Feline diabetes. Part 2: monitoring and management with other diseases
Background: Diabetes mellitus (DM) in cats is commonly seen in primary care practice and presents several clinical and practical challenges to owners and vets. In recent years feline DM has seen paradigm shifts in management and monitoring. Aim of the article: In this second article of a series on feline DM, we look at the monitoring options that are ...
Ian Ramsey, Anna Kraemer
wiley +1 more source
Multicenter Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson\u27s Disease [PDF]
Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients
Hutton, J. T. +13 more
core +1 more source
: Drying off dairy cows may challenge animal welfare due to high milk yields. A total of 111 loose-housed Holstein cows yielding >15 kg/d of milk were included in a 2 × 2 × 2 factorial design during dry-off to investigate the effects of reduced feeding ...
Margit Bak Jensen +4 more
doaj +1 more source
Effect of dopamine agonist dose and treatment duration on fibrous tissue formation in prolactinomas
Background: Currently, dopamine agonists are the established first-line therapy for prolactin-secreting pituitary adenomas. However, long-term treatment may be associated with the development of fibrotic changes within the adenoma tissue, which ...
Farida A. Nasybullina +4 more
doaj +1 more source
Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma
Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription.
Fu'an Xie +21 more
wiley +1 more source
Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial.
BackgroundBeneficial effects of dopamine agonist treatment on migraine have been reported but remain to be properly tested. The aim of this study was to examine the effect of cabergoline as preventive treatment for migraine.MethodsIn a double-blind ...
Astrid Johannesson Hjelholt +5 more
doaj +1 more source
Oral cabergoline for the management of equine pituitary pars intermedia dysfunction: Five cases
Background: Oral pergolide has become the mainstay of treatment for equine pituitary pars intermedia dysfunction (PPID). It has a high success rate but some horses are, or become, refractory to the effects.
Eleanor M. Kellon
doaj +1 more source
Feline diabetes. Part 1: diagnosis and treatment options
Background: Diabetes mellitus (DM) in cats is commonly seen in primary care practice and presents several clinical and practical challenges to owners and vets. In recent years feline DM has seen paradigm shifts in management and monitoring. Aim of the article: This article, the first of a two‐part series on feline DM, looks at how the pathogenesis ...
Ian Ramsey, Anna Kraemer
wiley +1 more source
Spontaneous reduction of prolactinoma post cabergoline withdrawal [PDF]
Prolactinomas are common pituitary tumors usually highly responsive to dopamine agonists. Around 70-90% of the prolactinomas exhibit decrease in tumor size, though variably with these agents.
Deepak Kothari +4 more
core +1 more source

